Followers | 4053 |
Posts | 151245 |
Boards Moderated | 4 |
Alias Born | 08/05/2009 |
Friday, June 16, 2017 8:19:47 AM
Published: June 16, 2017 7:04 a.m. ET
By
TOMI
KILGORE
REPORTER AND EDITOR
Shares of Celsion Corp. CLSN, +97.07% rocketed 42% in premarket trade Friday, after the cancer drug development company filed to withdraw plans for a stock offering. The company had originally filed on April 5 an S-1 statement with the Securities and Exchange Commission for the sale of shares, which was amended as recently as Wednesday for the sale of 2.45 million common shares and pre-funded and base warrants to buy over 4 million shares. In Friday's filing, the company stated that it submitted the withdrawal "because it does not intend to pursue the contemplated offering at this time." Earlier this week, the company said it had regained the minimum-bid compliance for the continued listing of its stock on the Nasdaq. That followed a 1-for-14 reverse stock split on May 30. The stock has plunged 52% year to date through Thursday, while the iShares Nasdaq Biotechnology ETF IBB, -0.77% has climbed 11% and the S&P 500 SPX, -0.22% has gained 8.7%.
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM